(Q36226708)

12 August 2017

1 reference

title

Gene therapy for malignant glioma: current clinical status (English)

1 reference

12 August 2017

0 references

Seppo Yla-Herttuala

2

0 references

author name string

Kalevi J Pulkkanen

series ordinal

1

1 reference

12 August 2017

1 October 2005

1 reference

12 August 2017

1 reference

12 August 2017

12

1 reference

12 August 2017

585-598

1 reference

12 August 2017

4

1 reference

Epidemiologic study of primary intracranial neoplasms.

12 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Glioma classification: a molecular reappraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Current and future strategies for the treatment of malignant brain tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Cancer gene therapy — current status in the clinics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Replicative adenoviruses for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Myeloprotection with drug-resistance genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Immunology of viral-vector-mediated gene transfer into the brain: an evolutionary and developmental perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Prodrug activation enzymes in cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Angiogenesis in cancer and other diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Targeting angiogenesis: genetic intervention which strikes at the weak link of tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Specific gene suppression using antisense strategy for growth suppression of glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

7 January 2021

Retroviruses as vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Clinical trials with retrovirus mediated gene therapy--what have we learned?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Production of first generation adenovirus vectors: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Modified adenoviruses for cancer gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Oncolytic herpes simplex virus vectors for cancer virotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Reovirus as an oncolytic agent against experimental human malignant gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

RNA viruses as virotherapy agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Intergeneric poliovirus recombinants for the treatment of malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Repetitive intrathecal injections of poliovirus replicons result in gene expression in neurons of the central nervous system without pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Gene transfer to the brain using feline immunodeficiency virus-based lentivirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Non-viral gene therapy: polycation-mediated DNA delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Gene therapy progress and prospects: nonviral vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Non-viral vectors in cancer gene therapy: principles and progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Rat glioma cell death induced by cationic liposome-mediated transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase “Suicide” Gene Therapy for Recurrent Glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Long-term survival after gene therapy for a recurrent glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Clinical protocol. Liposomal gene therapy with the herpes simplex thymidine kinase gene/ganciclovir system for the treatment of glioblastoma multiforme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): relevance for gene and cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

HSV1716 persistence in primary human glioma cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

The p53 gene and its role in human brain tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Adenovirus-mediated p53 gene therapy for human gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Response criteria for phase II studies of supratentorial malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Gene expression profiling of gliomas strongly predicts survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Adenovirus gene transfer causes inflammation in the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for ch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Towards global and long-term neurological gene therapy: unexpected transgene dependent, high-level, and widespread distribution of HSV-1 thymidine kinase throughout the CNS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Cancer gene therapy: hard lessons and new courses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Immune responses to gene therapy vectors: influence on vector function and effector mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Neural stem cell biology may be well suited for improving brain tumor therapies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Targeting of biotinylated compounds to its target tissue using a low-density lipoprotein receptor-avidin fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): treatment with hsFlt3L inhibits intracranial glioma progression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Imaging transgene expression with radionuclide imaging technologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

Sensitivity and reproducibility in adenoviral infectious titer determination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.07.357

10.1016/J.YMTHE.2005.07.357

7 January 2021

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16095972